Since 1999, Inotek’s scientists and physicians have been working to harness the cytoprotective properties of adenosine. Today, our most advanced drug candidate, trabodenoson, is a highly selective adenosine mimetic that has been shown to reduce intraocular pressure in patients with ocular hypertension and open-angle glaucoma, by enhancing the eye’s natural pressure-regulating system.
Expert Leadership
Inotek is led by accomplished executives and directors dedicated to the company’s success, and has partnered with some of the best eye doctors in the country on our Scientific Advisory Board.